A multi-center, un-controlled, open-labeled trial of the long-term safety of Lamazym aftercare treatment of subjects with alpha-Mannosidosis who previously participated in Lamazym-trials
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Velmanase alfa (Primary)
- Indications Alpha-Mannosidosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Zymenex A/S
- 01 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.
- 01 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 10 Jun 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.